Straumann Holding AG (OTCMKTS:SAUHY) Stock Short Interest Report for October

Straumann Holding AG (OTCMKTS:SAUHY) was the recipient of a significant decline in short interest in the month of October. As of October 15th, there was short interest totaling 26,983 shares, a decline of 39.9% from the September 30th total of 44,911 shares. Based on an average daily trading volume, of 255,560 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Several brokerages have recently commented on SAUHY. Citigroup reaffirmed a “sell” rating on shares of Straumann in a research report on Wednesday, October 21st. UBS Group raised shares of Straumann from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft lowered shares of Straumann from a “buy” rating to a “hold” rating in a research note on Friday, August 21st. The Goldman Sachs Group upgraded shares of Straumann from a “neutral” rating to a “buy” rating in a report on Monday, September 14th. Finally, Berenberg Bank raised shares of Straumann to a “strong-buy” rating in a research note on Thursday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Straumann Stock Up 0.6%

Shares of OTCMKTS:SAUHY opened at $11.79 on Friday. Straumann has a twelve month low of $9.44 and a twelve month high of $13.61. The stock’s 50 day moving average is $11.42 and its 200-day moving average is $11.66.

About Straumann

Straumann Group is a Switzerland-based dental technology company headquartered in Basel. Founded in 1954, the company develops, manufactures and distributes products used in tooth replacement, restorative dentistry and oral tissue regeneration. Its offerings are designed for dental professionals, laboratories and patients across a range of clinical applications.

The company’s portfolio includes dental implants, implant-supported prosthetics, biomaterials for bone and tissue regeneration, orthodontic aligners and digital dentistry solutions.